You will need RealPlayer to view these videos.
Welcome
Session I
- George Daley: Introduction - Cellular Therapeutics: Clinical State of the Art and Challenges for the Future
- Rob Negrin: Hematopoietic Stem Cell Transplantation: Where We Have Been and Where We Are Going
- Jeff Bluestone: A Cure for Type I Diabetes
- Olle Lindvall: Stem Cell Therapy for Human Brain Disease: How Can We Make It Work?
Session II
- Edward Penhoet: Intro - Stem Cells and Therapies: Lessons from the FDA and Industry
- Jane Lebkowski: Preclinical Studies to Support Clinical TEsting of Stem Cell-Based Therapies
- Alan Smith: GMP Banking, Manufacturing and Quality Control of Stem Cells for Clinical Use
- Donald Fink: Developing Stem Cell-Based Therapies: Engaging the FDA
Session III
- Fred Gage: Intro - Stem Cells as Tools for Disease Research and Therapy
- Rudolph Jaenisch: SCNT for Understanding Disease
- Inder Verma: Molecular Manipulation of Embryonic Stem Cells
- Peter Schultz: Small Molecules and High-Throughput Screening in Embryonic Stem Cells
Session IV
- Peter Andrews: Intro - Self-Renewal of Stem Cells
- Haifan Lin: Understanding Stem Cell Self-Renewal: Progress and Prospect
- Andras Nagy: Development of Tools for Studying hESC Self-Renewal
- Martin Pera: Development of Conditions for Defined Culture and Scale-Up
Session V
Session VI
- Ian Duncan: Intro - Bridging the Gap Between Bench and Bedside
- David Scadden: The Stem Cell Niche: A Drugable Target?
- Jon Odorico: Hurdles to Overcome in Applying hES Cells for Treatment of Diabetes
- Hans Keirstead: Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitors: A Defined Cell Population for a Defined Need
Session Summaries
Welcome
- Zach Hall, President, California Institute for Regenerative Medicine (CIRM)
- Joan Samuelson, Independent Citizens' Oversight Committee (ICOC)
- Robert Klein, ICOC
Session I - Cellular Therapeutics: Clinical State of the Art and Challenges for the Future
- Chair: George Daley, Harvard Medical School
- Rob Negrin, Stanford University
- Jeff Bluestone, UCSF
- Olle Lindvall, University of Lund, Sweden
Session II - Stem Cells and Therapies: Lessons from the FDA and Industry
- Chair: Edward Penhoet, ICOC
- Jane Lebkowski, Geron Corporation
- Alan Smith, Cognate Therapeutics, Inc.
- Donald Fink, Food and Drug Administration
Session III - Stem Cells as Tools for Disease Research and Therapy
- Chair: Fred Gage, Salk Institute
- Rudolph Jaenisch, The Whitehead Institute, MIT
- Inder Verma, Salk Institute
- Peter Schultz, The Scripps Research Institute
Session IV - Self-Renewal of Stem Cells
- Chair: Peter Andrews, University of Sheffield, United Kingdom
- Haifan Lin, Duke University School of Medicine
- Andras Nagy, Mount Sinai Hospital, Toronto, Canada
- Martin Pera, The Monash Institute of Medical Research, Australia
Session V - How Can We Control Differentiation of ES Cells?
- Chair: Owen Witte, UCLA
- Nissim Benvenisty, Hebrew University of Jerusalem, Israel
- Irving Weissman, Stanford University
- Michael Clark, University of Michigan
Session VI - Bridging the Gap Between Bench and Bedside
- Chair: Ian Duncan, University of Wisconsin
- David Scadden, Harvard Medical School
- Jon Odorico, University of Wisconsin
- Hans Keirstead, UC Irvine
Summaries and Closing Remarks
Roger Bingham
Fred Gage
Andras Nagy
Inder Verma
Owen Witte
